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AEFAbstract Background: In early stages of septic shock, impaired myocardial function plays an
important prognostic role. AEF and Plasma BNP level may be a valuable prognostic factor for
patients with sepsis.
Objective: We aimed also to evaluate the value of atrial ejection force (AEF) B-type natriuretic
peptide (BNP) in predicting the outcome of sepsis, severe sepsis and septic shock patients.
Methods: 40 patients presenting with sepsis, severe sepsis or septic were included in the study.
The patients had undergone transthoracic Echocardiographic examinations and BNP measure-
ments on the 1st and 3rd day of admission. The patients were retrospectively divided into survivors
and non survivors.
Results: There was a signiﬁcant statistical difference in BNP level (P= 0.0001) between the two
groups. BNP showed a statistically signiﬁcant rise in the non survival group from day 1 to day 3
(p= 0.002) and a statistically signiﬁcant decrease from day 1 to day 3 in the survived group
(p= 0.001). As regards the echo ﬁndings there was a statistically signiﬁcant difference AEF 3rd
day between survivors and non survivors (P= 0.0001). The ROC curve showed that BNP 1st
day, 3rd day are good tests for prediction of mortality in patients with sepsis.
Conclusion: Atrial ejection force on the ﬁrst day of admission, unlike BNP level, might not be
used as an independent predictor of mortality in patients with sepsis. BNP level correlates with
the severity of sepsis. According to our study, AEF in the third day may be a good predictor for
survival of patients presenting with sepsis.
 2014 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Sepsis is deﬁned as ‘‘the systemic inﬂammatory response
syndrome (SIRS) that occurs during infection.’’Sepsis is
not a homogenous disease; rather, it is a complex clinical
syndrome with distinct immunological features [1,2]. The
ambiguities of clinical ﬁndings and unclear risk stratiﬁcation
30 M.B. Salim et al.in sepsis have been major problems in sepsis intervention
trials [3].
In early stages of septic shock, impaired myocardial func-
tion plays an important prognostic role. In this context, B-type
natriuretic peptide (BNP) has been shown to be a neurohumo-
ral marker for left ventricular dysfunction, because myocardial
strain and ischemia both increase BNP concentration [4] Ven-
tricular dysfunction with reduced ejection fraction and biven-
tricular dilatation is present in most patients with severe
sepsis and septic shock. In survivors, this depression in cardiac
function is reversible over the course of seven to ten days. Even
though some prognostic factors have been identiﬁed in patients
with sepsis-induced myocardial dysfunction, their measure-
ment often includes costly and cumbersome techniques. Thus,
there is a need for an inexpensive, simple, rapid, and readily
available marker to predict mortality in septic shock. There
is a growing evidence supporting the hypothesis that BNP
could be an early predictor of mortality in septic shock. If pro-
ven, the hypothesis would have important clinical and public
health implications [5]. Plasma BNP level may be a valuable
prognostic factor for severe sepsis and septic shock patients [6].
There have been many studies in animals and a few in
humans which have conﬁrmed the presence of diastolic dys-
function - particularly in those patients that go on to die from
sepsis. In the presence of adequate ﬂuid resuscitation there is
an increase in end diastolic volume and this is probably a nor-
mal response to a decrease in contractility. However, in the
non-survivors of sepsis there is a normal or low-end diastolic
volume that is the result of a decrease in ventricular diastolic
compliance. Thus, there is a decreased end diastolic volume
at the same ﬁlling pressure [7].
Assessment of diastolic function through measurement of
the components of ventricular ﬁlling has largely neglected
the vigor of atrial systole, in part because this has been difﬁcult
to quantify. However, atrial ejection force deﬁned as the force
exerted by the left atrium to accelerate blood into the left ven-
tricle during atrial systole can be assessed non-invasively by
combined two-dimensional imaging and Doppler echocardiog-
raphy. This index of atrial function, based on classic Newto-
nian mechanics, provides a physiologic assessment of atrial
systolic function [8].
2. The aim of this work
Is to assess the utility of atrial function (diagnosed by atrial
ejection force) in predicting mortality in the ICU population
with sepsis. Our hypothesis was that as the atrium shares the
same pathophysiological effects as the ventricles, assessment
of the atrial function may be used as an alternative easy
method of assessing the severity of myocardial dysfunction
in sepsis and may therefore help to predict mortality. We
aimed also to evaluate the value of B-type natriuretic peptide
(BNP) in predicting the outcome of sepsis, severe sepsis, and
septic shock patients.
3. Patients and methods
This was a prospective study involving forty patients with sep-
sis admitted to the intensive care unit in the Theodor Bilharz
research institute (TBRI) from March 2012 to September
2013. This study was approved by the local ethics committeeand an informed consent was obtained from every patient or
his next of kin if the patient was unable to give consent before
being included in the study.
3.1. Inclusion criteria
Patients with
1-Sepsis: Documented or suspected infection associated
with Systemic inﬂammatory response syndrome (SIRS) when
two or more of the following criteria are met:
A. Body temperature >38 C or <36 C.
B. Tachycardia >90/minute.
C. Hyperventilation: respiratory rate >20/minute or arte-
rial hypocapnia <32 mmHg.
D. White blood cell count >12,000/dL or <4000/dL or
immature forms >10%.
2-Severe sepsis: Sepsis associated with organ dysfunction.
3-Septic shock: Sepsis associated with circulatory failure
characterized by persistent arterial hypotension (decreased sys-
tolic blood pressure below 90 mmHg or P40 mmHg from
baseline, or mean arterial pressure <60 mmHg despite ade-
quate ﬂuid resuscitation) unexplained by other causes [9].
3.2. Exclusion criteria
1. Patients with history of ischemic heart disease.
2. Patients with history of congestive cardiac failure.
3. Patients with history of rheumatic heart disease.
4. Terminally ill patients due to causes other than current
sepsis.
5. Patients with AF.
Included patients were subjected to the following:
 Written consent (by the patient or his relatives).
 History.
 Full clinical assessment.
 Laboratory tests on admission and follow up including cul-
tures as appropriate.
 Acute physiology and chronic health evaluation II
(APACHE II) scores and the length of stay (LOS) in ICU
were collected.
 Plasma BNP level (by Enzyme Immunoassay (EIA)) was
measured upon admission and on the third day after admis-
sion to the intensive care unit. Transthoracic echocardiog-
raphy (TTE): All echocardiographic measurements were
performed by one operator and according to the recommen-
dations of the American Society of Echocardiography [10].
M-mode, two-dimensional echocardiography, and doppler
ultrasound studies were made using a high-resolution
(ALT 5000 HDI) Toshiba Nemo 30 scanner equipped with
a 2.5 mHz transducer.
 With M-mode, measurements of interventricular septum
(IVS) and left ventricle posterior wall thicknesses (PWT)
separately at diastole and systole were done and left ventri-
cle end-diastolic (LVEDD) and end systolic (LVESD)
diameters were determined. Left ventricular ejection frac-
tion (EF%) was measured from M-mode dimensions using
Teichholz formula [11].
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long axis view at end systole. Left atrium volume was mea-
sured with Simpson’s method using apical 4-chamber and
apical 2-chamber views at the ventricular end systole (max-
imum LA size). Estimation of LA volume by Simpson’s
method of disk is well validated and recommended by the
American Society of Echocardiography (ASE) guidelines
[12].
 Mitral valve diameter (MVD) was measured manually from
a four-chamber view using two-dimensional echocardiogra-
phy. Mitral valve area (MVA) was calculated as
3.14(MVD/2)2 on the assumption that the mitral valve ori-
ﬁce is circular.
 Sample volume was placed at the mitral annulus level and A
waves were recorded from a four-chamber view at a paper
speed of 50 mm/s using pulsed-Doppler echocardiography.
The peak velocity of A waves was obtained from averaging
three consecutive beats.
Atrial ejection force was estimated using the following
equation:
Atrial ejection force
¼mass acceleration; substituting for mass and acceleration;
Atrial ejection force
¼ 0:5qðdensity of blood¼ 1:06 g=cm3Þ
mitral orifice areaðPeak A velocityÞ2:
The unit of force would thus be measured in g-cm/s2 or
dynes [13].Table 1 Vital signs and labs distribution in non survivors and surv
Non survivors (Mean ± SD




HR (beat/min) 121.5 ± 15
RR (breath/min) 25.2 ± 4.5
SBP (mmHg) 99.4 ± 21
DBP (mmHg) 60 ± 15.8
Urea (mg/dl) 81.9 ± 40.7
Creat (mg/dl) 1.7 ± 0.7
Na (mEq/L) 134.2 ± 5.8
K (mEq/L) 3.2 ± 0.9
Random blood sugar(mg/dl) 257.6 ± 120.7
HB (gm/dl) 11.4 ± 2.6
TLC (109 /L) 18.2 ± 6.7
Staﬀ (%) 11.9 ± 3.8
Plat (109 /L) 205.5 ± 121.2
INR 1.3 ± 0.5
SGOT (IU/L) 48.8 ± 20.8
SGPT (IU/L) 56.2 ± 26.8
Alb (gm/dl) 3 ± 0.5
Bil (mg/dl) 1.4 ± 0.8
PO2 (mmHg) 66.2 ± 14.1
PCO2(mmHg) 37.9 ± 10.9
Hco3(mmol/L) 19.9 ± 6.7
Length of stay in ICU (day) 8.1 ± 5.6
APACHI II 20 ± 4.2 One of the difﬁculties that faced us during the study is mea-
surement of the density of the blood because it may change
with sepsis; ﬁnally we decided to set the blood density at
1.06 g/cm3 (normal range), which the other studies stated
to be comparable to their results.
 All echocardiographic measurements were done on the ﬁrst
day of admission and on the third day.
 Because the mean of the length of stay in our ICU in the
year before the study was 3 days, we decided to follow up
the Echo and BNP in the third day.
 Other data collected included the requirements for mechan-
ical ventilation (ventilation hours) and vasopressor and the
patient’s outcome (survived or not survived).
All collected questionnaires were revised for completeness
and consistency. Pre-coded data were entered on the computer
using ‘‘Microsoft Ofﬁce Excel Software’’ program (2010) for
windows. Data were then transferred to the Statistical Package
of Social Science Software program, version 16 (SPSS) to be
statistically analyzed. Data were summarized using mean,
standard deviation, median and percentiles for quantitative
variables and frequency and percentage for qualitative ones.
Comparison between groups was done using independent
sample t-test and one way ANOVA (if parametric) and Mann
Whitney test and Chi square test or Fischer exact test for qual-
itative ones. Pearson correlation coefﬁcient was calculated to
get the association between different quantitative variables.
Discriminate analysis was conducted through receiver operat-
ing characteristics (ROC) analysis. P values equal to or less
than 0.05 were considered statistically signiﬁcant.ivors.
) Survivors (Mean ± SD) P value
50.3 ± 15.1 0.216
14 0.523
9
119.9 ± 14 0.747
26.6 ± 3.7 0.288
120 ± 21.1 0.004
77.1 ± 16.4 0.002
45.8 ± 18.4 0.0001
1.5 ± 0.4 0.580
134.8 ± 5.5 0.613
3.5 ± 1 0.355
275 ± 147.2 0.627
11.5 ± 1.8 0.926
15.8 ± 4.6 0.187
10.9 ± 3 0.344
272.8 ± 135 0.070
1.5 ± 0.6 0.305
38 ± 22.8 0.135
49.5 ± 36.8 0.530
4.9 ± 7.5 0.305
4.6 ± 9.4 0.171
82.3 ± 17.3 0.003
33.8 ± 11.3 0.261
20.1 ± 6.5 0.908
7.9 ± 10.9 0.944
14.5 ± 2.9 0.0001
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 We studied 40 patients: 17 had sepsis, 14 had severe sepsis,
and nine had septic shock during the study. We used the cri-
teria of the 2001 SCCM/ESICM/ACCP/ATS [9] interna-
tional sepsis deﬁnitions conference to deﬁne and classify
the patients.
 In our study, 17 patients did not survive while 23 patients
survived. There was no statistically signiﬁcant difference
between the two groups concerning age and the gender.
The two compared groups were homogenous.
 In our study, 21% of survivors and 94% of non-survivors
were mechanically ventilated.
 In our study, 13% of survivors and 88% of non-survivors
were on vasopressors; we used Norepinephrine as the ﬁrst
choice vasopressor (grade 1B) (SSc2012) [14] (see Tables
1–7).
4.1. Logistic regression analysis
It was done to search for the signiﬁcant predictors of mortality
in sepsis BNP on the ﬁrst and third day; EF ﬁrst and third day
and AEF third day were entered in the logistic regression anal-
ysis and BNP third day was found to be a signiﬁcant predictor
for mortality in patients with sepsis (p-value was 0.001).
4.2. ROC curve for the predictors of mortality in patients with
sepsis
We found that a BNP ﬁrst day level of 449 pg/ml can signify a
sensitivity of 94% and a speciﬁcity of 79% in predicting theTable 5 Relation between degree of sepsis and ECHO ﬁndings.
Sepsis Sev
AEF 1st D (Kdyn) 9.8 ± 1.4 10.7
AEF 3rd D (Kdyn) 10.3 ± 2.1 10.8
Table 2 BNP with mortality.
Non survivors (Mean ± SD)
BNP 1st D (pg/ml) 622.2 ± 157.4
BNP 3rd D (pg/ml) 802.8 ± 256
Table 3 Relation between degree of sepsis and BNP.
Sepsis (Mean ± SD) Severe sepsis
BNP 1st D (pg/ml) 310.7 ± 203.5 490.3 ± 197
BNP 3rd D (pg/ml) 291.4 ± 213 574 ± 311
Table 4 ECHO ﬁndings with mortality.
Non survivors (Mean ± SD)
EF 1st D (%) 54.5 ± 4.3
EF 3rd D (%) 51.2 ± 4.2
AEF 1st D (Kdyn) 9.9 ± 1.4
AEF 3rd D (Kdyn) 8.4 ± 1mortality of patients presenting with sepsis, severe sepsis,
and septic shock while a BNP third day level of 544 pg/ml
can signify a sensitivity of 82% and a speciﬁcity of 92% in pre-
dicting the mortality of patients presenting with sepsis, severe
sepsis, and septic shock. An AEF third day level of 9.8Kdyn
can signify a sensitivity of 91% and a speciﬁcity of 89% in pre-
dicting the survival of patients presenting with sepsis, severe
sepsis, and septic shock (see Figs. 1 and 2).
5. Discussion
5.1. Atrial ejection force (AEF) and sepsis
Determination of the left atrial systolic functions by measuring
atrial ejection force (AEF) at the left ventricle relaxation enables
us to assess atrial contribution to the left ventricle ﬁlling, thus
AEF serves equally as an indirect parameter of the left ventricle
diastolic functions to assess left ventricle relaxation.
Regarding the importance of age as an inﬂuencing factor
for AEF measurements, we do not believe there is a statisti-
cally signiﬁcant difference in the mean age of our patients in
comparison with patients in other comparable studies. The
age ranged from 20 to 82 years with a mean age of
52.9 ± 15 years, and this was slightly higher than that
observed in Omar et al. [15]in which the mean age was
49 ± 16 years.
In the current study, there was a statistically insigniﬁcant
association between AEF measured on the ﬁrst day and mor-
tality admission; AEF was higher in the group of survivors
than in non-survivors.
To our knowledge, only one study by Omar et al. [15]
explored the left atrial function in sepsis. Our results are inere sepsis Septic shock P value
± 1.8 10.4 ± 1.1 0.661
± 2.1 9.1 ± 1.7 0.187
Survivors (Mean ± SD) P value
326 ± 199.1 0.0001
290 ± 80.3 0.0001
(Mean ± SD) Septic shock (Mean ± SD) P value
658.8 ± 233 0.000
813.7 ± 284.2 0.000
Survivors (Mean ± SD) P value
60.6 ± 7.3 0.004
62.4 ± 7.8 0.0001
10.1 ± 1.5 0.572
11.6 ± 1.5 0.0001
Table 6 Relation between AEF in ﬁrst and third day in non survivors and survivors.
Non survivors (Mean ± SD) Survivors (Mean ± SD)
AEF 1st D (Kdyn) 9.9 ± 1.4 10.1 ± 1.5
AEF 3rd D (Kdyn) 8.4 ± 1 11.6 ± 1.5
P value 0.000 0.000
Figure 2 ROC Curve of the sensitivity and speciﬁcity of the
AEF third day in detecting survival Area under curve for AEF 3rd
day are 0.97.
Table 7 BNP and Echo ﬁndings in relation to the APACHI II
score.
APACHE II
BNP 1st D (pg/ml) Pearson correlation 0.612
Sig. (2-tailed) 0.001
BNP 3rd D (pg/ml) Pearson correlation 0.691
Sig. (2-tailed) 0.001
EF 1st D (%) Pearson correlation 0.651
Sig. (2-tailed) 0.00
EF 3rd D (%) Pearson correlation 0.725
Sig. (2-tailed) 0.00
AEF 1st D (Kdyn) Pearson correlation 0.009
Sig. (2-tailed) 0.954
AEF 3rd D (Kdyn) Pearson correlation 0.508
Sig. (2-tailed) 0.001
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cant association between the left atrial ejection fraction and
the mortality in such patients and concluded that it cannot
be used as an outcome predictor. Omar et al. [15] also found
that AEF was slightly higher in the survivors compared to
non survivors. Their hypothesis was that serial AEF may pre-
dict survival in patients with septic shock.
In our study, AEF on the third day showed a statistically
signiﬁcant decrease in the non-survived group (p= 0.000)Figure 1 ROC Curve of the sensitivity and speciﬁcity of the BNP in detecting mortality. Area under curve for BNP EF1st day and BNP
3rd are 0.88 and 0.94 respectively.
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(p= 0.000) in comparison with that measured on the ﬁrst
day. Omar et al. [15] also found that AEF increased in the sur-
vived group and decreased in the non-survived group on the
fourth day of admission in comparison with the ﬁrst day.
No studies have compared the results of AEF on the third
day and mortality; we found a statistically signiﬁcant differ-
ence in AEF measured on the third day between survivors
and non-survivors, which was 8.4 ± 1 k dynes and
11.6 ± 1.6 k dynes, respectively (P= 0.0001). There was a sta-
tistically signiﬁcant negative association between the
APACHE II scores AEF 3rd day (R= 0.508, P= 0.001).
Our study also found a negative correlation between AEF
measured on the third day and BNP measured on the third
day (P= 0.001).
The receiver operating characteristic curve demonstrated
that an AEF third day level of 9.8Kdyn can signify a sensitivity
of 91% and a speciﬁcity of 89% in predicting the survival of
patients presenting with sepsis, severe sepsis, and septic shock.
(Area under curve for AEF third day is 0.97).
5.2. Brain natriuretic peptide BNP in patients with sepsis
The role of the BNP as a diagnostic test of heart failure was
extensively explored in the recent years. In 2002, Maisel
et al. [16] performed a large multicenter investigation involving
1586 patients who presented to an emergency department (ED)
with acute dyspnea. They found that a serum BNP level is use-
ful to assist in differentiating between heart failure and pul-
monary disease as a cause of dyspnea. In this study, a BNP
level of 100 pg/ml or higher was 90% sensitive and 73% spe-
ciﬁc for diagnosing congestive heart failure (CHF).
In our study, we decided to measure the BNP because it is a
more reliable measurement in renal failure patients (a common
ﬁnding in critically ill septic patients) than NT––pro BNP––as
shown by DeFilippi et al. [17] who concluded in their review
that the NT-proBNP rises disproportionately to BNP at lower
estimated glomerular ﬁltration rate (eGFR).
In our study, survivors had a signiﬁcantly lower BNP level
(mean value of 326.01 ± 199.07 pg/ml) than the non-survivors
(mean value of 622.25 ± 157.45 pg/ml) on admission
(p= 0.0001) and also on the third day of admission, the
BNP in non-survivors (mean value of 802.81 ± 256.04) pg/
ml group was statistically higher than the survivors group
(mean value of 289.97 ± 80.39 pg/ml) (p= 0.0001).
The results of our study are in agreement with other studies
concerning the role of BNP in septic patients. Abu-Khabar
et al. [18] found BNP in survivors on admission ranged
between 80 and 936 with a mean value of 345.01 ± 222.1 pg/
ml. This remained stable during day 1, 2 and 3 but decreased
on discharge. In non-survivors BNP ranged between 145 and
1210 pg/ml with a mean of 708.62 ± 305.17 pg/ml on admis-
sion and changed signiﬁcantly during the study period. The
mean level decreased on day 1 then increased in day 2 and 3.
Survivors had a signiﬁcantly lower BNP level than the non-
survivors on admission and at all three intervals. Also in Omar
et al. [15] the authors found that admission BNP concentra-
tions were signiﬁcantly higher in the non-survivors
(P< 0.0001).
Zhang et al. [19] recently showed that elevated baseline
BNP was associated with signiﬁcantly increased risk of mortal-ity. The association of elevated baseline BNP with increased
risk of mortality has been proven in multiple studies [20,21].
This association may be attributable to sepsis-related cardiac
depression that is characterized by myocardial stiffness and
mechanical insufﬁciency. In response to myocardial stretch,
the plasma BNP level will increase [19].
Cuthbertson et al. [22] showed that there was a trend
toward higher BNP levels on ICU admission and at 24 h in
survivors. Although this is not in agreement with our study,
the trend was not statistically signiﬁcant in his study.
Sturgess et al. [23] found levels of BNP, of 448 ± 607 pg/ml
and 1289 ± 1155 pg/ml in survivors and non-survivors respec-
tively, but the difference was not statistically signiﬁcant. The
difference in the values of the BNP in the different studies
could be explained by the different kits of analysis with differ-
ent sensitivity. The non-signiﬁcance in the last study may also
be attributed to the small number of patients included
(n= 21).
5.3. Brain natriuretic peptide BNP changes during time
In our study, we calculated the sensitivity and speciﬁcity of the
BNP on the ﬁrst day; we found that a level of 449 pg/ml had a
sensitivity of 94% and a speciﬁcity of 79% in predicting the
mortality of patients presenting with sepsis, severe sepsis,
and septic shock. While a BNP third day level of 544 pg/ml
had a sensitivity of 82% and a speciﬁcity of 92% in predicting
the mortality of patients presenting with sepsis, severe sepsis,
and septic shock, this means that the BNP on the ﬁrst day
was more sensitive but less speciﬁc than its level on the third
day. While in Abu-Khabar et al. [18] Operating Characteristic
curve showed that a BNP level of 250.5 had a sensitivity of
82.8% and a speciﬁcity of 64.7% in predicting the mortality
of patients presenting with severe sepsis and septic shock.
5.4. Brain natriuretic peptide BNP and age
Regarding the importance of the age as an inﬂuencing factor
for the BNP measurements, we cannot consider that there is
a statistically signiﬁcant difference in the mean age of our
patients in comparison with patients in other comparable stud-
ies. The age ranged from 20 to 82 years with a mean age of
52.9 ± 15 years, which was slightly lower than that observed
in the studies concerning the epidemiological data of patients
with severe sepsis including that of Brueckmannet al. [24] with
a mean age of the enrolled patients at 55.0 ± 16.3 years. In
Abu-Khabar et al. [18] the age ranged from 26 to 79 years with
a mean age of 60.1 ± 13.3 years.
In our study, we found a statistically signiﬁcant association
between the degree of sepsis and BNP serum level on both the
ﬁrst day and the third day. There are many studies that relate
BNP levels to the degree of sepsis and septic shock, and these
studies mainly focused on hospitalized patients in the intensive
care unit [25].
Rivers et al. [26] found that the BNP in septic shock
patients in the emergency department occurred at higher rates
than in patients with sepsis.
In the current study, we found a statistically signiﬁcant rise
in BNP in the non-survival group from day 1 to day 3
(p= 0.002) and a statistically signiﬁcant decrease from day 1
to day 3 in the survived group (p= 0.001). Abu-Khabar
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non-survival group from day 1 to day 3 (p= 0.001) and also
found a statistically signiﬁcant BNP decrease from day 1 to
the time of discharge in the survived group (p= 0.001). This
is in agreement with Omar et al. [15] results, where BNP was
signiﬁcantly higher in the non-survivors (P< 0.0001) and
remains signiﬁcantly higher on the fourth and seventh days
(P= 0.01 and 0.001, respectively, in the non-survivors).
BNP tends to decrease throughout the course in survivors
(592 on day 1, 318 on day 4, and 93 pg/ml on day 7).
6. Limitations
Limitation of the study was the relatively small sample size and
the Effect of mechanical ventilation, vasopressors and other
medications on AEF is not known. Further studies are needed.
7. Conclusion
Atrial ejection force on the ﬁrst day of admission, unlike BNP
level, might not be used as an independent predictor of mortal-
ity in patients with sepsis. BNP level correlates with the sever-
ity of sepsis. According to our study, AEF in the third day may
be a good predictor for survival of patients presenting with
sepsis.
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